Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) has enrolled the first participant in a Phase 1a/1b study evaluating ARQ-234, an investigational treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE